Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos Sells 4,647 Shares of Stock

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $5.30, for a total transaction of $24,629.10. Following the completion of the transaction, the chief financial officer now directly owns 74,197 shares in the company, valued at $393,244.10. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Cibus Stock Down 7.7 %

NASDAQ:CBUS opened at $4.90 on Thursday. Cibus, Inc. has a 52 week low of $2.86 and a 52 week high of $23.18. The stock’s fifty day moving average is $4.05 and its two-hundred day moving average is $8.60. The stock has a market capitalization of $129.63 million, a price-to-earnings ratio of -0.22 and a beta of 1.79.

Hedge Funds Weigh In On Cibus

Several hedge funds have recently bought and sold shares of the company. FMR LLC grew its position in Cibus by 16.9% in the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock valued at $12,757,000 after acquiring an additional 566,328 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Cibus by 3.7% in the first quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock valued at $16,215,000 after purchasing an additional 26,017 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Cibus in the second quarter valued at approximately $5,083,000. Bank of New York Mellon Corp purchased a new stake in Cibus during the 2nd quarter worth approximately $529,000. Finally, Old West Investment Management LLC lifted its holdings in Cibus by 3.6% during the 2nd quarter. Old West Investment Management LLC now owns 53,247 shares of the company’s stock worth $524,000 after buying an additional 1,868 shares in the last quarter. Institutional investors and hedge funds own 33.81% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on CBUS. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Cibus in a research report on Monday. Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a report on Friday, July 19th. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Cibus in a research report on Tuesday, October 22nd. Finally, Alliance Global Partners reduced their price objective on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research report on Tuesday, September 24th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.